611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Sciences
Resources
Basic InformationLatest News
Type 2 Diabetes May Be Bad for Brain Health'Brain Age' May Help Predict When You'll DieParkinson's Disease May Originate in Gut, Study SaysBlood-Based Genome Testing Feasible for Rapid Mutation AssayBlood Test May Gauge Death Risk After Surgery150-Year-Old Drug May Shorten 'Off' Time for Parkinson's PatientsBrain May Be Organized by Functions, Not Body PartsBody Temperature Might Give Clues to ComaCould Young Blood Boost the Aging Brain?A 'Brainwave' to Help Fight PTSDDizziness in Parkinson's May Be Due to Cerebral HypoperfusionMisunderstood Gene Tests May Lead to Unnecessary MastectomiesScientists Extend Lives of Mice With ALSFDA Approves 1st Direct-to-Consumer Genetic Risk TestsFDA OKs 1st At-Home Genetic Tests for 10 Disorders'SuperAgers' Have Less Whole-Brain Cortical Volume LossHigh Thyroid Hormone Levels Tied to Stiffer ArteriesBrain Changes May Mark Risk of Financial Exploitation in SeniorsRegular Exercise Slows Decline Even in Advanced Parkinson's DzBrain-Computer Link Restores Some Movement to Quadraplegic ManScientists Spot Gene for Rare Disorder Causing Deafness, BlindnessNew Technology Makes Gene Mapping Cheaper, Faster: StudyTurning Back the Aging Clock -- in MiceNew Parkinson's Drug Xadago ApprovedBrain 'Rewires' to Work Around Early-Life BlindnessBrain Training for Cancer Survivors' Nerve DamageASA: Vagus Nerve Stimulation May Enhance Stroke RecoveryGene Therapy: A Breakthrough for Sickle Cell Anemia?Gene Therapy Shows Promise for Aggressive LymphomaThe Brain Can Produce Its Own Sugar: ReportCould Parkinson's Disease Raise Stroke Risk?NHL Veterans Pledge Their Brains to ResearchMRIs Can Be Safe for People With Heart Devices …Scientists Shed Light on Possible Cause of NearsightednessBrain Chip Helps Paralyzed 'Type' With Their MindDoes Mercury in Fish Play a Role in ALS?Repeat Head Hits May Not Put NFL Players at Risk of Motor ProblemsMRI Can Identify Early Signs of ASD in High-Risk InfantsEvidence of CTE Identified in Former Soccer PlayersSpace Reshapes Astronauts' Brains: StudyDiagnostic Potential for Blood-Based NfL in Parkinson's DiseaseIs It Parkinson's or Something Else? Blood Test Might Tell30 Former NFL Players Pledge Their Brains for ResearchAstronaut Twins Give Clues to Health Hazards of SpaceflightBrain-Computer Interface Lets Locked-In Patients CommunicateGene Discoveries Offer New Height InsightsBrain Scans Let 'Locked-In' ALS Patients CommunicateCaffeine Found to Reduce Age-Related InflammationfMRI May Be Better Way to Map Brain Prior to Epilepsy SurgeryVagus Nerve Might Play a Role in Fighting Inflammatory Disease
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

New Parkinson's Drug Xadago Approved

HealthDay News
by -- Scott Roberts
Updated: Mar 22nd 2017

WEDNESDAY, March 22, 2017 (HealthDay News) -- Xadago (safinamide) tablets have been approved by the U.S. Food and Drug Administration as an add-on drug to treat Parkinson's patients who take levodopa or carbidopa but have instances of increased symptoms anyway, a condition doctors call "off" episodes.

An "off" episode, when Parkinson's medication doesn't seem to work well, may include symptoms such as tremor and difficulty walking, the agency said in a news release.

Some 50,000 Americans are diagnosed each year with Parkinson's, and about 1 million Americans have the neurological condition, the FDA said, citing the U.S. National Institutes of Health. Typically diagnosed in people 60 and older, it occurs when brain cells that produce the chemical dopamine become impaired or die.

The absence of enough dopamine leads to lack of smooth, purposeful movement during activities such as walking, eating, writing or shaving, the FDA said.

Xadago's effectiveness was established in a clinical study of 645 people who were taking the Parkinson's drug levodopa but were still having "off" periods. Compared to people who took a placebo, users of Xadago had fewer instances of Parkinson's symptoms, without uncontrolled involuntary movements that doctors call dyskinesia.

Certain people shouldn't take Xadago, including those with severe liver problems, who are taking a cold medication called dextromethorphan, who are taking a so-called MAOI drug or who are taking certain antidepressants, the FDA said.

Xadago's most common side effects included involuntary movement, falls, nausea and insomnia. More serious adverse reactions included worsening high blood pressure, falling asleep during daily activities, hallucinations, psychotic behavior, compulsive behavior, fever and confusion.

The FDA granted approval of Xadago to Newron Pharmaceuticals, based in Milan, Italy.

More information

Visit the FDA to learn more.